Senseonics Holdings, Inc. (SENS)

Senseonics Holdings, Inc. (SENS) stock has experienced significant fluctuations, trading between $28.00 and $5.25 in the past six months, with a price around $7.34 in early February 2026. Key events include a public offering and private placement in May 2025, where Senseonics closed a public offering of 115,000,000 shares of common stock at $0.50 per share, generating $57.5 million in gross proceeds, and Abbott Laboratories acquired 40,539,265 shares for approximately $20.3 million in a private placement. Senseonics reported a Q3 2025 EPS of -$0.43, missing analysts' expectations. The company's common stock transferred to the Nasdaq Global Select Market in November 2025. The Eversense 365 CGM system received CE Mark approval in Europe in January 2026 and entered the Automated Insulin Delivery (AID) market with the twiist system. The company reported Q4 2024 revenue of $8.3 million and full-year 2024 revenue of $22.5 million, with the Eversense 365 approval and launch in the U.S. leading to a 56% increase in the patient base.

Senseonics Holdings, Inc. experiences seasonality due to higher utilization of patient assistance programs early in the year, which can reduce average selling prices (ASPs) and margins. The company manages manufacturing based on patient demand, aiming for 60 to 90 days of inventory. Following the launch of Eversense 365, Senseonics was increasing inventory levels and expected to reach target levels by the end of Q2 2025.

Senseonics Holdings, Inc. is a medical technology company specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. Their product line includes the Eversense, Eversense XL, Eversense E3, and Eversense 365 CGM systems, featuring an implantable sensor, a smart transmitter, and a mobile application for real-time glucose monitoring. The Eversense 365 system offers a year-long sensor wear duration.

Senseonics Holdings, Inc. serves healthcare providers and patients in the United States and internationally through a network of distributors and strategic fulfillment partners. The company is headquartered in Germantown, Maryland, United States.

Senseonics Holdings, Inc. focuses on improving the lives of people with diabetes through its continuous glucose monitoring (CGM) systems. The Eversense 365 system is the world's first and only year-long CGM system. The approval and launch of Eversense 365 in the U.S. in 2024 led to a 56% increase in their global patient base. Early indicators for the U.S. Eversense 365 launch were favorable, with new patient shipments reaching a historical monthly high in December 2024, and 81% of new patients switching from competitor CGMs. The company completed the submission of its CE Mark application for Eversense 365 in the European Union in Q1 2025 and initiated a collaboration with Mercy Health. Analyst ratings for Senseonics are generally positive, with a consensus rating of "Buy".

Major institutional owners of Senseonics Holdings, Inc. include Hood River Capital Management LLC, Vanguard Group Inc., UBS Group AG, Group One Trading, L.p., Simplex Trading, Llc, Beck Mack & Oliver Llc, Tudor Investment Corp Et Al, Stonebridge Capital Advisors LLC, Geode Capital Management LLC, First Light Asset Management LLC, BlackRock Institutional Trust Co. NA (BlackRock, Inc.), Charles Schwab Investment Management, Inc., Masters Capital Management, L.L.C., and State Street Global Advisors, Inc. Notable individual owners include Robert L. Smith and Timothy Goodnow.